Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBIT: 2016-2024

Historic EBIT for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to -$50.5 million.

  • Akebia Therapeutics' EBIT rose 135.58% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.7 million, marking a year-over-year increase of 151.00%. This contributed to the annual value of -$50.5 million for FY2024, which is 9.11% down from last year.
  • As of FY2024, Akebia Therapeutics' EBIT stood at -$50.5 million, which was down 9.11% from -$46.3 million recorded in FY2023.
  • In the past 5 years, Akebia Therapeutics' EBIT ranged from a high of -$46.3 million in FY2023 and a low of -$377.8 million during FY2020.
  • Over the past 3 years, Akebia Therapeutics' median EBIT value was -$50.5 million (recorded in 2024), while the average stood at -$59.2 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 31.97% in 2020, then surged by 69.46% in 2022.
  • Akebia Therapeutics' EBIT (Yearly) stood at -$377.8 million in 2020, then rose by 29.99% to -$264.5 million in 2021, then spiked by 69.46% to -$80.8 million in 2022, then skyrocketed by 42.74% to -$46.3 million in 2023, then fell by 9.11% to -$50.5 million in 2024.